Key Compounding Pharmacy (Puget Sound Drug Corporation), Federal Way, WA
Is Key Compounding Pharmacy (Puget Sound Drug Corporation) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Key Compounding Pharmacy (Puget Sound Drug Corporation) hold a Washington pharmacy license?
State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use. The California State Board of Pharmacy also lists nonresident license NRP 3050 for Key Compounding Pharmacy Llc, Federal Way, WA, status Active and license NSC 101974 for Key Compounding Pharmacy Llc, Federal Way, WA, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5394 for Key Compounding Pharmacy, Federal Way, WA, status Surrendered, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022838 for KEY COMPOUNDING PHARMACY LLC, FEDERAL WAY, WA, status ACTIVE and license 054016440 for PUGET SOUND DRUG CORP, FEDERAL WAY, WA, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000527 for KEY COMPOUNDING PHARMACY, FEDERAL WAY, WA, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000779 for Key Compounding Pharmacy, Federal Way, WA, status Expired, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301008618 for Key Compounding Pharmacy LLC, Federal Way, WA, status Active, as of Nov 10, 2026.
Has Key Compounding Pharmacy (Puget Sound Drug Corporation) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Mar 31, 2020), 1 state referral letter (Mar 31, 2020) and 1 FMD-145 letter (Mar 31, 2020) for Key Compounding Pharmacy (Puget Sound Drug Corporation). State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use. The Colorado State Board of Pharmacy’s license dataset also lists 3 actions: “CLS Voluntary Surrender/Relinquishment” dated Aug 9, 2013, case 2013-578 on nonresident license OSP 5394, “Formal Complaint-Charges with OAC” dated May 22, 2013, case 2013-578 on nonresident license OSP 5394 and “ITRM Summary Suspension” dated May 22, 2013, case 2013-578 on nonresident license OSP 5394. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Reprimand” dated Feb 3, 2020, case 2018009677 on nonresident license 054016440. The Maryland Board of Pharmacy’s posted orders against permit holders also lists “PRE-CHARGE CONSENT ORDER” dated Feb 3, 2020 on nonresident permit P04568. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Puget Sound Drug Corporation; Key Compounding Pharmacy
- Location
- Federal Way, WA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 31, 2020
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 12 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Puget Sound Drug Corporation, (dba Key Compounding Pharmacy), a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Mar 31, 2020 | State referral letter | State Referral Letter Issued 03/31/2020 | Not linked by FDA |
| Mar 31, 2020 | Warning letter close-out | Warning Letter Close Out Issued 03/31/2020 | Not linked by FDA |
| Mar 31, 2020 | FMD-145 letter | FMD-145 Letter Issued 03/31/2020 | Not linked by FDA |
| Jun 13, 2019 | Form 483 | 483 Issued 06/13/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Puget Sound Drug Corporation, Federal Way, WA (FEI number 3006089725), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 13, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006089725 | 1092826 |
| Mar 8, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006089725 | 1007008 |
Form 483s FDA has published for this site
- Jun 13, 2019: Form 483 to Puget Sound Drug Corporation, published Dec 18, 2019. fda.gov
- Jun 13, 2019: Form 483 to Puget Sound Drug Corporation, published Jul 12, 2019. fda.gov
- Apr 14, 2017: Form 483 to Puget Sound Drug Corporation, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Mar 8, 2017 to Jun 13, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 28, 2019 to Jun 13, 2019: 1 observation
- Firm on the cover
- 53, 0 S 33 6th St, F ederal W ay, W A 9 8003-6383 TYPE ESTABLISHMENT IN SPECTED P roducer o f s terile a nd n on-sterile p roducts
- FEI number
- 3006089725
- FDA district office on the cover
- 22215 26th Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/133607/download
Observation 1
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
Your firm uses non-pharmaceutical grade <Redacted B4> in the production of veterinary drug products. For example, on 5/21/2019, your firm produced Potassium Bromide (vet) Beef250 mg/ml soln, lot 05/20/2019@72 using <Redacted B4> that is not labeled as pharmaceutical or FCC grade. The label of the <Redacted B4> you used lists ingredients in addition to <Redacted B4>
Inspection Jan 26, 2017 to Mar 8, 2017: 11 observations
- Firm on the cover
- Puget Sound Drug Corporation dba Key Compounding Pharmacy 530 South 336th Street, Federal Way, WA 98003 Producer of sterile and non-sterile drug products
- FEI number
- 3006089725
- FDA district office on the cover
- othell, WA 98021 P
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Actionable microbial contamination was present in the ISO 5 area or in adjacent areas during aseptic production without adequate product evaluation and remedial action.
Specifically, Your firm recovered following objectionable microorganisms from the classified areas and failed to conduct a risk/impact assessment on the products produced and distributed from November 2016 to February 2017. During this time when objectionable microorganisms were recovered from your facility, approximately <R edact ed B4> batc hes of sterile drug products were produced in the ISO 5 hoods from 1/25/17 to 2/28/17.
A. Microorganisms recovered from the ISO 5 hoods:
1)On 1/26/17, in-house surface samples collected from the <Redacted B4> showed 5 colony forming units (CFUs) per plate from the <Redacted B4> and 4 CFUs per plate from the <Redacted B4> (total 9 CFUs). Bacillus hornecklae was identified from these surface samples. I
the
2) Additionally, Bacillus hornecklae was recovered from the in-house surface samples collected on 1/26/17
fro m the <Redacted B4> (2 CFUs per pla te a nd f ro m the <R edacted B4> on 1/25/17 (1 CFU per p late from t he <Redacted B4> and 1 CFU per pla te from the <Redacted B4> ...
Observation 2
Aseptic practices are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, A. On 01/26/17, the Pharmacy Technician used a small stainless steel hand-held mini mop with a sterile cleaning pad. The technician soaked the cleaning pad with steril e <Redacted B4> and sanitized the walls of the <Redacted B4> ISO 5 hood. After cleaning, the technician hung the mop with a dirty clean ing pad inside the hood and filled a
g
sterile injectable drug, TriMix, lot # 01-25-2017@10. The technician completed the sterile filling process, cl eaned the ISO 5 hood and did not remove the dirty mop from the hood.
B. On 01/26/17, the Pharmacy Technician failed to clean the ceiling and return grates of the <Redacted B4> ISO 5 hoo d with sterile <Redacted B4> before or after the production of TriMix, a sterile injectable drug product, l ot # 01-25-2017@103. Your current practice is to clean these surfaces of the ISO 5 hoo d <Redac ted B4> d uring <Redacted B4> cleaning.
C. ...
Observation 3
Environmental monitoring is not adequately performed in your aseptic areas.
Specifically, your firm performed <Redacted B4> cleaning and collected environmental samples approximately with in <Redacted B4> of cleaning. For example:
A. Your firm performed <Redacted B4> cleaning on 3/14/16 and in-house surface samples for environmental monitorin g were collected 3/15/16.
B. Your firm performed <Redacted B4> cleaning on 1/11/17 and surface samples for environmental monitoring were col lected by your third party contractor on 1/12/17.
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already di stributed.
Specifically, your firm failed to conduct adequate investigation regarding sterility assurance of a sterile drug product. On 11/3/16, your firm produced Sodium Phenylbutyrate, Lot t11-02-2016@87 that failed sterility whe n sent to an outside testing laboratory. The same lot of Sodium Phenlbutyrate, Lot t11-02-2016@87, when test ed in-house, passed the sterility test. Your firm opened an investigation, Internal Quality Related Event (QRE) on 01/04/17 approximately two months later. However, the investigation failed to identify a possible root cause and the potential discrepancy between sterility test results for the in-ho us e testing and outside testing laboratory .
Observation 5
Aseptic practices are deficient regarding the system for maintaining a en vironment suitable for production of sterile drugs.
Specifically, A. On 2/22/17, we observed· various examples ofpaper and cardboard, stored and/or. in use, in the ISO 7 "Compounding Room", to include card board boxes containing (15) (4 ). and a small sign with the Key Compounding Pharmacy name and logo on it
B. Additionally, on 2/22/17 we observed the Pharmacist Technician and the Lead Pharmacist exchanging a paper note pad back and forth through the <Redacte d B4> where the Pharmacy Technician was observed writ
ing <Reda cted B4> requests for supplies on the note pad while it was in th e <Redacted B4>. The Pharma cy Technician remained in the ISO 7 "Compounding Room" and the Lead Pharmacist was in the ISO 8 "Pr ep Room". We observed this practice 4-5 times within the course of approximately 20 minutes.
Observation 6
Personnel performing aseptic operations failed to disinfect or change gloves frequently enough to prevent contamination.
Specifically, A. On 01/26/17, the Pharmacy Technician donned sterile gloves on top of non-sterile gloves. After sanitizing t he <Redacted B4> ISO 5 hood and <Re dacted B4> etc, the technician did not disinfect < Redacted B4> sterile gloves and start ed <Redacted B4> a sterile injectable drug product, TriMix, lot # 0 1 - 25-2017@103 <Redacted B4>
~CJ
I
B. On the following occasions microorganisms were recovered from the sterile glove fingertips of the Pharmacy
Technician involved in producing sterile drugs: (b)(6~(b) • 1) On 1/25/17, 1 CFU was recovered from the <Redacted B4> fingertip of the technician, <Redacted B4>. The micr oorganism identified was Bacillus benzoevorans.
12) On 1/26/17, 1 CFU was recovered from the <Redacted B4> fingertip and 2 CFUs from the <Redacted B4> fingertip of
(5) ( 4) ] for microbial identification. 4) On 2/2/17, 1 CFU was recovered from the <Red a c ted B4> fingertip and 1 CFU from the <Redacted B4> fingertip of the
tec hnician, <Redacted B4>. Your firm discarded these samples and no microbial identi fication was performed.
Observation 7
The final containers/closures used for drug products intended to be sterile have not been sterilized or depyrogenated.
Specifically, there is no assurance that the container and closures that undergo in-house sterilization or depyrogenation are sterile, as follows:
A.Your firm did not use <Re dacted B 4> with every batch of containers and closures that are sterilized in-house using <Redacted B4>. The <Redacted B4> are used <Redacted B4>. Also there is no documentation about the <Redaction B4> when <Redactede B4> were used.
B. Your firm failed to assign any batch identifiers and did not establish hold times for containers, closures and all re-usable sterilized equiYour firm faile d to assi gn any batch identifiers and did not establish hold times for containers, closures and all re-usable sterilized equipment, after <Redacted B4> and/or depyrogenation.
C. There is no data to support the continued sterility of various sizes of amber-colored glass vials such as 2mL , 5mL, 10mL, 20mL, 30mL and 50 mL that undergo in-house sterilization and depyrogenation.
D.There is no data to support continued sterility of the <R edacted B4> stoppers that undergo in-house sterilization.
Observation 8
Inadequate pressure differentials between lower quality air rooms and higher quality air rooms were observed.
Specifically, on 1/26/17 we observed inadequate pressure differentials between the ISO 8 Ante Room lower quality air room and the higher quality air in the ISO 7 "Compounding Room". Also, the air pressure differential between the unclassified non-sterile compounding area into the ISO 8 "Prep Roomn" were apparently not working. The following issues were noted: The following issues were not~:
Puget Sotmd Drug Col],oration dba Key C0mpoun4ing Pharmacy
530 South 336th Street
TYPE OF ESTABUSHMENT INSPECTED Producer ofster.ile and non-sterile drug products
A. The Magnebelic gauges did not appear to be registering movement ~d we did not feel any pressure difference enteritig in or exiting out ofthese rooms. Your firm had issues with the airpressure dif(erential since 2015 as evidenced by your HVAC contractorO o) (40 Invoice# (6} (4), dated 5/18/15 which states that the "clean room side robing in the wall was pinched and folded over itself' and that ''the lab side[(5) ( 4 ~was not engaged fully on · the brass barb". ...
Observation 9
Equipment and tools used are not of appropriate materials for use in sterile drug production. use
Specifically, on 1/27/17, during non-sterile to sterile production of a sterile opthalmic solution, Atropine sulphate 0. 5%, lot t01-26-2017@93, we observed that the Pharmacy Technician <Red acted B4> atropine sulphate in a <
Redacted B4> hood using wood en <Redacted B4> that is particle generatin g and difficult to clean. This wooden <Redact ed B4> had visible scratches which do not allow the <Redacted B4> to be cleaned properly.
Observation 10
ISO-5 classified areas were not certified under dynamic conditions.
Specifically, smoke studies have not been performed in the ISO 5 hoods under dynamic conditions since <Redacted B4>
Observation 11
Highly potent drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically, your firm handles potent drug substances including hormones and there are no procedures or controls in place to prevent cross-contamination. On 2/1/17, we observed following issues related to the control and potential cross-contaminatiion of hormonal drug substances in the <Redacted B4> hoods in the non-sterile area:
in place to prevent cross-contamination. On 2/1/17, we observed following issues related to the control and potential cross-contamination ofhonnona1
' substances in th~ . (o) ( 4) l.hoods in the
•< non-sterile area:
I ~g
I
A.After filling the Progesterone EYM 60mg capsules, lot 1-27-2017@100, the Pharmacy Technician was o bserved cleaning the equipment by blowing air on the equipment. This resulted spreading of the hormone <Red acted B 4> dust al over the hood. During production of non-sterile Progesterone EYM 60mg capsules, lot 1-27-2017@100, <Redacted B4
> dust accumulation was observed in the hood, on th e pre-filters (before HEPA filters), along the seams of the h oods.
B. ...
State board of pharmacy records
State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.
Nonresident licenses and board actions in other states
These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NRP 3050 | Non Resident Pharmacy | Key Compounding Pharmacy Llc | Federal Way, WA | Active |
| NSC 101974 | Non Resident Licensed Sterile Compounding | Key Compounding Pharmacy Llc | Federal Way, WA | Active |
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5394 | OSP | Key Compounding Pharmacy | Federal Way, WA | Surrendered |
- Aug 9, 2013: “CLS Voluntary Surrender/Relinquishment”, license OSP 5394, case 2013-578, Key Compounding Pharmacy, Federal Way, WA. Board document
- May 22, 2013: “Formal Complaint-Charges with OAC”, license OSP 5394, case 2013-578, Key Compounding Pharmacy, Federal Way, WA. Board document
- May 22, 2013: “ITRM Summary Suspension”, license OSP 5394, case 2013-578, Key Compounding Pharmacy, Federal Way, WA. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054022838 | LICENSED PHARMACY | KEY COMPOUNDING PHARMACY LLC | FEDERAL WAY, WA | ACTIVE |
| 054016440 | LICENSED PHARMACY | PUGET SOUND DRUG CORP | FEDERAL WAY, WA | CHANGE OF OWNERSHIP |
- Feb 3, 2020: “Reprimand”, license 054016440, case 2018009677, PUGET SOUND DRUG CORP, FEDERAL WAY, WA. Reason given in the record: “respondent Puget Sound Drug Corp. d/b/a Key Compounding Pharmacy's pharmacy license no. 054016440 is reprimanded due to Respondent's Missouri sister state discipline.” Board list
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0000527 | NONRESIDENT PHARMACY | KEY COMPOUNDING PHARMACY | FEDERAL WAY, WA | ACTIVE (CURRENT) |
Maryland Board of Pharmacy, board actions read Nov 15, 2026 (Maryland).
- Feb 3, 2020: “PRE-CHARGE CONSENT ORDER”, permit P04568, KEY COMPOUNDING PHARMACY, Federal Way, WA. Board document
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0000779 | Non Resident Pharmacy | Key Compounding Pharmacy | Federal Way, WA | Expired |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301008618 | Pharmacy | Key Compounding Pharmacy LLC | Federal Way, WA | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Maryland Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.